Advanced Therapies 2026 took place 17 -18 March 2026 in London, UK. DDW asked industry experts for their key takeaways from the event. Michael Baker, Director, Advanced Therapies, FUJIFILM Biotechnologies Walking away from Advanced Therapies Week UK 2026, the focus is no longer just on… Read More
Phacilitate’s 22nd Advanced Therapies Week (ATW) took place in San Diego on 9-12 February, bringing together industry stakeholders from around the world for to showcase progress in cell and gene therapies (CGT). From manufacturing bottlenecks and regulatory transparency to the rise of in vivo… Read More
Dr Jeff Domsic, Product Manager Charles River Laboratories, discusses ATP-bioluminescence testing aligned with new regulatory guidelines. Over the past decade, the emergence of advanced therapy medicinal products (ATMPs) has fundamentally changed the approach to developing, manufacturing, administering, and treating diseases. These advanced modalities show significant promise… Read More
An opinion by Dr Ioannis Papasotiriou. This article is sponsored by RGCC International. How is a new drug developed in oncology? While this may seem like a simple question, it is important to recognise that the process is far more complex than it initially… Read More
This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers five articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: The promise and growth of cell and gene therapies… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been… Read More
News round-up for 19-23 June by DDW Digital Content Editor Diana Spencer. Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been the announcement of the FDA’s approval of the first gene therapy for Duchenne muscular dystrophy, and a caution… Read More
Sarepta Therapeutics’ Elevidys has become the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US. The Food and Drug Administration (FDA) has granted accelerated approval to Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus (AAV) based gene therapy for the treatment of… Read More
The proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorised in the EU, claims the Alliance for Regenerative Medicine (ARM). According to ARM, all seven gene therapies for rare genetic diseases would have been rejected under the baseline methodologies proposed… Read More
Contract development and manufacturing organisation (CDMO) SCTbio and cell therapy company Cyto-care.eu have teamed up with the aim of improving the quality of cryopreservation in Europe. The goal of the collaboration is to address the critical need for efficient collection, cryopreservation, quality control and logistics capabilities… Read More
New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production… Read More
Listen to this article on the DDW Podcast: What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? DDW’s Megan Thomas finds out. Skills gap Bruce Levine, International Society for… Read More
With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. … Read More
Where globally is innovation occurring and what factors – industry, regulatory, and academia – are helping developers get their products to market? Here, DDW Editor… Read More
Recent OBE recipient and SLAS Europe 2022 keynote speaker Steve Rees tells DDW’s Megan Thomas his thoughts on the themes of SLAS Europe 2022, the value of returning to face-to-face meetings, the influence the organisation has on his work and the industry’s key changes since the SLAS was formed in… Read More
The UK has been highlighted as a leader in clinical trials for Advanced Therapy Medicinal Products (ATMPs), after a report published by the Cell and Gene Therapy Catapult (CGT Catapult) displayed the sector’s continued growth in the UK. The report CGT Catapult’s 2021 Advanced Therapy Medicinal Product (ATMP) report… Read More
